SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: John O'Neill who wrote (14848)2/12/1998 1:06:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
John, You can always get the latest at home.att.net
LGND gapped higher on record volume today because they published a paper showing that Targretin was better than Tamoxifen (the $800 million compound approved for treatment of breast cancer) in treating a well accepted animal model for breast cancer. LGND has mentioned starting a Phase II trial and they have been on CNBC several times, including a very nice piece last night, after the close.